Cargando…

Analysis of disease progression in patients with transthyretin cardiac amyloidosis

Detalles Bibliográficos
Autores principales:	Gilmore, Julian D, Maurer, Mathew S, Vest, John, Karsten, Verena, Powell, Christine, Strahs, Andrew, Gollob, Jared, Hawkins, Philip N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642039/ http://dx.doi.org/10.1186/1750-1172-10-S1-O10

Ejemplares similares

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
por: Gillmore, Julian D, et al.
Publicado: (2015)

DISCOVERY: a study examining the prevalence of transthyretin mutations in subjects suspected of having cardiac amyloidosis
por: Akinboboye, Olakunle, et al.
Publicado: (2015)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study
por: Cortese, Andrea, et al.
Publicado: (2015)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Pre-contrast ShMOLLI T1 mapping in cardiac AL amyloidosis
por: Karamitsos, Theodoros, et al.
Publicado: (2012)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis
por: Driggin, Elissa, et al.
Publicado: (2019)

LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study
por: Fontana, Marianna, et al.
Publicado: (2015)

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
por: Cheng, Richard K., et al.
Publicado: (2021)

Equilibrium contrast CMR for the detection of amyloidosis in mice
por: Campbell, Adrienne E, et al.
Publicado: (2011)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study
por: Banypersad, Sanjay M, et al.
Publicado: (2014)

Multiorgan ECV as measured by EQ-MRI in systemic amyloidosis
por: Banypersad, Sanjay M, et al.
Publicado: (2013)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
por: Bandera, Francesco, et al.
Publicado: (2022)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

Empirical use of anakinra in AA amyloidosis of uncertain aetiology
por: Lane, T, et al.
Publicado: (2015)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Liver‐directed drugs for transthyretin‐mediated amyloidosis
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Monitoring for arrhythmia in transthyretin cardiac amyloidosis with remote patch devices
por: Bruce, S, et al.
Publicado: (2023)

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
por: Kristen, Arnt V., et al.
Publicado: (2012)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Delayed hyper-enhancement cardiac magnetic resonance provides incremental prognostic value in patients with cardiac amyloidosis
por: Austin, Bethany A, et al.
Publicado: (2009)

Comparison of right ventricular involvement in AL and transthyretin-type cardiac amyloidosis by cardiovascular magnetic resonance
por: Appelbaum, Evan, et al.
Publicado: (2009)

Transthyretin cardiac amyloidosis: an update on diagnosis and treatment
por: Yamamoto, Hiroyuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2vimq9b4e53ffsh05jn0pabsr0